logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Exemestane CAS 107868-30-4

Exemestane CAS 107868-30-4

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 107868-30-4

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
107868-30-4
Appearance::
White To Light Yellow Crystal Powder
Molecular Formula::
C20H24O2
Molecular Weight::
296.40300
EINECS NO::
643-090-2
MDL NO::
MFCD00886994
CAS NO::
107868-30-4
Appearance::
White To Light Yellow Crystal Powder
Molecular Formula::
C20H24O2
Molecular Weight::
296.40300
EINECS NO::
643-090-2
MDL NO::
MFCD00886994
Exemestane CAS 107868-30-4

Product Description:

Product Name: Exemestane CAS NO: 107868-30-4

 

 

Synonyms:

6-methylenandrost-1,4-diene-3,17-dione;

androsta-1,4-diene-6-methylene-3,17-dione;

(8R,9S,10R,13S,14S)-10,13-diMethyl-6-Methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione;

 

 

Chemical & Physical Properties:

Appearance: White to light yellow crystal powder

Assay :≥99.0%

Density: 1.13 g/cm3

Boiling Point: 453.7℃ at 760 mmHg

Melting Point: 155.13℃

Flash Point: 169℃

Refractive Index: 1.572

Storage Condition: Store in original container in a cool dark place.

Vapor Pressure: 2.02E-08mmHg at 25℃

 

 

Safety Information:

HS Code: 2937900090

WGK Germany: 3

Caution Statement: P201; P305 + P351 + P338; P308 + P313

Symbol: GHS07, GHS08

Signal Word: Danger

Hazard Declaration: H319; H360

 

 

Exemestane is an irreversible steroi-d aromatase inhibitor. Its structure is similar to that of aromatase’s natural substrate, androstenedione, and acts as a pseudosubstrate. Postmenopausal women’s estrog-en is mainly converted from androg-en (produced by the adrenal cortex) by aromatase in the surrounding tissue. This drug irreversibly binds with the active site on aromatase to deactivate it, thus dramatically lower estrog-en levels in the blood circulation of postmenopausal women. By inhibiting aromatase to lower estrog-en levels, it can be used to treat hormone-dependent breast cancer in postmenopausal women.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.